



DRUG DISCOVERY

## **Preclinical Models**

Innovative solutions to accelerate drug discovery and development

By Dr Tim Atkinson

## **Tim Atkinson BSc MSc DProf MRSC MSB MCIM**

Dr Tim Atkinson has over 15 years experience of consultancy work for global pharmaceutical companies, healthcare organizations, and medical publishers. As a Pharmaceutical Market Analyst he has authored over 25 healthcare management reports and has expertise in drug discovery technologies, pharmaceutical reformulation, biomaterials, parallel trade, and numerous therapeutic areas. As a biomedical scientist he has published peer-reviewed journal papers in the areas of toxicology and cancer, immunology, biochemistry, neuroendocrinology, and gene therapy.

Dr Atkinson graduated with a BSc (Honours) in the Health Sciences, and holds an MSc with Distinction in Health and Disease from Birkbeck College, University of London. He earned his Professional Doctorate in Pharmaceutical and Healthcare Research from Middlesex University, London. He is a member of the Royal Society of Chemistry, Society of Biology, the Biochemical Society, British Society for Immunology, the European Society of Clinical Microbiology and Infectious Diseases, and the Chartered Institute of Marketing.

Copyright © 2010 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Preclinical models

<b>Executive summary</b>	<b>10</b>	
<b>Preclinical models in drug discovery and development</b>	<b>10</b>	
<b>In vivo models in preclinical research</b>	<b>11</b>	
<b>In vitro models in preclinical research</b>	<b>12</b>	
<b>In silico models in preclinical research</b>	<b>13</b>	
<b>Systems biology models in drug discovery</b>	<b>14</b>	
<b>Chapter 1</b>	<b>Preclinical models in drug discovery and development</b>	<b>16</b>
<b>Summary</b>		<b>16</b>
<b>Introduction: importance of preclinical models for toxicity screening in drug development</b>		<b>17</b>
Preclinical ADMET testing systems		17
The challenge: reducing drug attrition rates in preclinical screening		19
Importance of ADMET screening		22
Applying of ADMET to the drug discovery and development process		22
<b>Importance of in vivo models</b>		<b>23</b>
<b>Established in vivo and in vitro ADMET tools to screen compounds</b>		<b>25</b>
Toxicity and genotoxicity screening		26
Predicting toxicity with paracellular markers		27
<b>In vitro ADMET screening in preclinical drug development</b>		<b>27</b>
Advantages and disadvantages of conventional ADME screening tools in preclinical drug development		28
Oral absorption prediction		28
Metabolism prediction		29
<b>In vivo ADMET animal models</b>		<b>30</b>
Established ADMET study methods in animal models		32
Radiolabels		32
Cassette dosing		32
Semi-simultaneous dosing		33
Conclusion		34

Limitations of traditional in vitro and in vivo ADMET screening methods	34
<b>New approaches to predict ADMET in preclinical development</b>	<b>36</b>
Metabolomics	36
Advantages of metabolomics in drug discovery and development	37
Lead prioritization using metabolomics	37
Metabolomics and ADMET studies	37
Strengths and limitations of metabolomics for preclinical research	38
Metabolomics and “systems biology” – a unified approach to preclinical ADMET screening	40
Company focus: Merrimack Pharmaceuticals	41
Other emergent technologies used in preclinical drug discovery and development	42
Nanotechnologies in preclinical studies	42
Novel imaging systems	43
<b>Preclinical research and recent multinational pharmaceutical company activities</b>	<b>44</b>
Bayer AG and Nimbus Biotechnology	44
Pfizer/Johnson and Johnson and WuXi Pharma Tech	44
Roche	44
Sanofi-Aventis	45
UCB Pharma	45

## **Chapter 2                      In vivo models in preclinical research                      48**

<b>Summary</b>	<b>48</b>
<b>Vertebrate animal models in preclinical discovery and development</b>	<b>49</b>
Assessment of predictive value of animal models	49
Rodent models	50
The need for improved small animal models	50
Humanized rodent models	51
Advantages and disadvantages of zebrafish models in preclinical research	52
<b>Recent progress with vertebrate models</b>	<b>54</b>
ADMET screens and zebrafish models: company developments and technologies	54
Discovery Genomics	54
Evotec AG	55
Phylonix	56
Summit	56
ZF Biolabs	57
Zygon	58
ADMET screens in rodent models: selected company developments and technologies	59
Lexicon Pharmaceuticals	59
Taconic	59
Xenogen’s (now part of Caliper)	61
Sigma-Aldrich	62

<b>Invertebrate animal models in preclinical discovery and development</b>	<b>63</b>
Drosophila melanogaster (fruit fly)	63
Aktogen	64
En Vivo Pharmaceuticals	66
Exelixis	67
Medros Pharmaceuticals	67
Caenorhadbitis elegans (nematode)	68
Novel in vivo/ex-vivo focus: Locusta migratoria (locust)	68

## **Chapter 3                    In vitro models in preclinical research                    72**

<b>Summary</b>	<b>72</b>
<b>Importance of in vitro models in preclinical toxicity testing</b>	<b>73</b>
<b>In vitro technologies for drug discovery and development</b>	<b>74</b>
Recent company developments	74
Affymetrix	74
Beckman Coulter	75
Covance	75
Gene Logic	75
HemoGenix	76
Recent developments in drug transport and metabolism	76
Qualyst	76
Xenobiotic Laboratories	77
<b>Progress in cell-based in vitro assays</b>	<b>77</b>
Use of cultured cells for ADMET studies in preclinical research	77
In vitro distribution	80
In vitro solubility	80
In vitro ADMET assays and cell-type selection	81
<b>Recent developments in cell-based platforms for preclinical drug screening</b>	<b>83</b>
Cell-based assays and liver toxicity	83
Stem cells in drug discovery and development	84
Stem cells and ADMET in drug discovery and development	85
<b>Novel in vitro technologies in preclinical research</b>	<b>87</b>
Nanotechnologies and ADMET in drug discovery and development	87

## **Chapter 4                    In silico models in preclinical research                    92**

<b>Summary</b>	<b>92</b>
<b>In silico models in drug discovery and development</b>	<b>93</b>
Molecular modeling in silico	94

Computer models to predict ADMET	95
Methodological approaches to in silico models	95
<b>Recent commercial developments and activities</b>	<b>97</b>
Accelrys	97
Advanced Chemistry Development	97
Aureus Pharma	98
Chemical Computing Group	99
Entelos	99
Gene Network Sciences	101
Leadscope	102
Life Technologies Corporation	102
Molecular Discovery	103
Molecular Networks	104
Noray Bioinformatics	105
Schrödinger	105
Simcyp	105
Simulations Plus	106
TerraBase	107
Tripos	108

## **Chapter 5                    Systems biology models in drug discovery                    110**

<b>Summary</b>	<b>110</b>
<b>Systems biology: integrative science for drug discovery</b>	<b>111</b>
<b>Predictive biosimulation platforms to aid preclinical research</b>	<b>113</b>
Virtual organs and patients	114
<b>Pathway biology systems: recent commercial developments and activities</b>	<b>116</b>
Ariadne Genomics	116
GeneGo	117
Genomatix	119
Genstruct	120
Ingenuity Systems	122
Merrimack Pharmaceuticals	123
Physiomics	124
<b>Considerations for preclinical models in drug discovery and development</b>	<b>125</b>
Key points and recommendations	125

## **Appendix                    127**

<b>Abbreviations and acronyms</b>	<b>127</b>
<b>Primary research methodology</b>	<b>129</b>
References	130
Other sources	130

## List of Figures

Figure 1.1:	Established preclinical ADMET systems and models for drug discovery and development	20
Figure 1.2:	Common reasons for a drug candidate's failure	21
Figure 1.3:	Key advantages & disadvantages of animal models in preclinical drug development	24
Figure 1.4:	Animal models (%) used in preclinical ADMET studies	31
Figure 2.5:	Advantages and disadvantages of zebrafish for preclinical ADMET screening in drug discovery and development	53
Figure 2.6:	Preclinical ADMET screen types offered by Evotec AG	55
Figure 2.7:	Rationale for use of <i>Drosophila</i> as preclinical model for neurobiological disease	66
Figure 4.8:	Factors limiting the use of in silico ADMET models	96
Figure 5.9:	Drivers of systems biology in pharmaceutical R&D	112

## List of Tables

Table 1.1:	Routine screens to assess ADME of drug candidates in discovery	26
Table 2.2:	Key advantages of <i>Drosophila</i> in preclinical drug discovery and development	64
Table 3.3:	Commonly used cultured cells for in-vitro permeability assays	78

